Tiffany Reiter is an Associate in the Boston office of Fish & Richardson. Dr. Reiter’s practice emphasizes U.S. and foreign patent prosecution, opinion work, due diligence studies, and portfolio advisement.
Technical areas of Dr. Reiter’s prosecution and opinion work include molecular biology, biochemistry and biochemical pathways, genetics, cellular biology, virology, recombinant protein manufacturing, nucleic acid vectors and therapeutics, array technology, immunology, recombinant antibody screening and engineering, molecular medicine, screening and diagnostic assays and kits, biomarkers, transgenic plants and animals, cell lines, nanoparticle technology, surgical procedures, vaccines, and neuroscience.
Dr. Reiter has over seven years of patent prosecution experience in the life sciences. She has research experience as a post-doctoral fellow at the Harvard School of Public Health where she worked on a project combining the fields of neuroscience, molecular biology, and biochemistry; an intern at Northrup King where she worked on transgenic plant research; and as a student at the Mayo Graduate School where she studied the redox regulation of metalloenzymes using molecular biology, cellular biology, biochemistry, and a variety of spectroscopic methods.
Selected scientific and legal publications
Reiter et al., “Heme oxygenase-1 overexpression blocks NO-induced necrosis by preventing lipid peroxidation in human pulmonary epithelial cells,” J. Biol. Chem. 281(48):36603-36612, 2006.
Reiter et al., “Electrochemical studies of the mono-Fe, Fe-Zn, and Fe-Fe metalloisoforms of bacteriophage protein phosphatase,” Biochemistry 43: 782-790, 2003.
Reiter et al., “Mn2+ is a native metal ion activator for bacteriophage protein phosphatase,” Biochemistry 41:15404-15409, 2002.
Reiter et al., “Is calcineurin a peroxide-sensor in T-lymphocytes?” J. Biol. Inorg. Chem. 7: 823-834, 2002.
Reiter et al., “Redox regulation of calcineurin in T-lymphocytes,” J. Biol. Inorg. Chem. 4: 632-644, 1999.
Reiter et al., “2013 Year-In-Review: Patent Cases at the Federal Circuit,” Industrial Biotech. 10(2):79-82, 2014.
Reiter et al., “Patent eligibility of biological methods and compositions,” Industrial Biotech. 9(3):90-92, 2013.
Reiter et al., “The America Invents Act and Its Importance to Patent Prosecution in the Biotech Sector,” Industrial Biotech. 8(2):66-69, 2012.
Reiter et al., “The Federal Circuit Court of Appeals decides that isolated DNA claims are patentable,” Industrial Biotech. 9(3):272-275, 2011.
Reiter et al., “Strategies for expediting examination in U.S. patent applications,” Industrial Biotech. 7(5):349-353, 2011.
Reiter et al., “Isolated, purified, covalent bonds, or magic microscopes? What defines patentable nucleic acid molecules?” Industrial Biotech. 7(3):196-199, 2011.